Education
About Us
Working with TipRanks
Follow Us
bioMerieux SA (GB:0RUG)
:0RUG
Total Valuation
bioMerieux has a market cap or net worth of €14.14B. The enterprise value is ―.
Market Cap€14.14B
Enterprise Value―
Share Statistics
bioMerieux has 118,361,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding118,361,220
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
bioMerieux’s return on equity (ROE) is 0.10 and return on invested capital (ROIC) is 9.04%.
Return on Equity (ROE)0.10
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)9.04%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee281.32K
Profits Per Employee30.05K
Employee Count14,147
Asset Turnover0.69
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of bioMerieux is 28.20. bioMerieux’s PEG ratio is 6.08.
PE Ratio28.20
PS Ratio0.00
PB Ratio3.23
Price to Fair Value2.90
Price to FCF42.18
Price to Operating Cash Flow20.32
PEG Ratio6.08
Income Statement
In the last 12 months, bioMerieux had revenue of 3.98B and earned 432.20M in profits. Earnings per share was 3.67.
Revenue3.98B
Gross Profit2.22B
Operating Income588.80M
Pretax Income579.30M
Net Income432.20M
EBITDA897.50M
Earnings Per Share (EPS)3.67
Cash Flow
In the last 12 months, operating cash flow was 667.30M and capital expenditures -345.80M, giving a free cash flow of 321.50M billion.
Operating Cash Flow667.30M
Free Cash Flow321.50M
Free Cash Flow per Share2.72
Dividends & Yields
bioMerieux pays an annual dividend of €0.85, resulting in a dividend yield of 0.71%
Dividend Per Share€0.85
Dividend Yield0.71%
Payout Ratio23.23%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change23.26%
50-Day Moving Average115.89
200-Day Moving Average108.59
Relative Strength Index (RSI)51.92
Average Volume (3m)30.77K
Important Dates
bioMerieux upcoming earnings date is Sep 4, 2025, TBA Not Confirmed.
Last Earnings DateMar 7, 2025
Next Earnings DateSep 4, 2025
Ex-Dividend DateJun 09, 2025
Financial Position
bioMerieux as a current ratio of 2.20, with Debt / Equity ratio of 11.67%
Current Ratio2.20
Quick Ratio1.29
Debt to Market Cap0.03
Net Debt to EBITDA0.05
Interest Coverage Ratio36.80
Taxes
In the past 12 months, bioMerieux has paid 154.30M in taxes.
Income Tax154.30M
Effective Tax Rate0.27
Enterprise Valuation
bioMerieux EV to EBITDA ratio is 13.63, with an EV/FCF ratio of 38.04.
EV to Sales3.07
EV to EBITDA13.63
EV to Free Cash Flow38.04
EV to Operating Cash Flow18.33
Balance Sheet
bioMerieux has €449.80M in cash and marketable securities with €490.70M in debt, giving a net cash position of €40.90M billion.
Cash & Marketable Securities€449.80M
Total Debt€490.70M
Net Cash€40.90M
Net Cash Per Share€0.35
Tangible Book Value Per Share€25.38
Margins
Gross margin is 54.19%, with operating margin of 14.79%, and net profit margin of 10.86%.
Gross Margin54.19%
Operating Margin14.79%
Pretax Margin14.56%
Net Profit Margin10.86%
EBITDA Margin22.55%
EBIT Margin14.96%
Analyst Forecast
The average price target for bioMerieux is €131.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€131.00
Price Target Upside10.27% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―